Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study

Launched by CHINESE UNIVERSITY OF HONG KONG · Jun 11, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help manage heart failure, specifically for patients who have a weakened heart (known as reduced left ventricular ejection fraction). The study aims to see if using mobile technology and wearable devices can help doctors safely adjust heart medications for these patients without requiring them to visit the clinic as often. This is important because increasing medication dosages can be tricky due to potential side effects, and many patients may not have easy access to healthcare services.

To participate in this study, patients need to have certain symptoms of heart failure and specific test results, such as a certain level of a heart-related marker in their blood. However, some patients may not be eligible, including those who have had certain recent heart procedures or have other significant health issues. If patients join the trial, they can expect to receive support through mobile technology to monitor their health and help optimize their heart failure treatment from home. This could lead to better heart failure management and make healthcare more accessible for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Clinical symptoms of Dyspnoea (exertional or at rest) and 1 of the following signs:
• • Congestion on chest X-ray
• • Rales on chest auscultation
• • Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale)
• • Elevated jugular venous pressure.
• • 2. NT-proBNP which is measured within the same hospitalization with level \>300ng/L or 600ng/L if ongoing atrial fibrillation/atrial flutter.
• • 3. Left ventricular ejection fraction less than 40% by any form of imaging.
• Exclusion Criteria:
• • 1. Documented history of HF with previous HF admission.
• • 2. Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute MI.
• • 3. Cardiac interventions (listed below) in past 30 days prior or planned during the study period.
• • 1. Major cardiac surgery, or Tran Aortic Valve Implantation, or Percutaneous Coronary Intervention, or MitraClip
• • 2. Current or expected heart transplant, LVAD, IABP, or patients with planned inotropic support in an outpatient setting.
• • 4. Haemodynamically severe uncorrected primary cardiac valvular disease.
• • 5. eGFR \<30 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis.
• • 6. Documented allergy or intolerance to beta-blocker, renin-angiotensin-aldosterone system inhibitor, mineralocortical receptor antagonist, or angiotensin receptor/neprilysin inhibitor.
• • 7. Pregnant or nursing women.
• • 8. Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
• • 9. Non-ambulatory patients.
• • 10. Patients who are unable to operate simple electronic devices; or unable to assess a mobile network service in the place of residence.
• • 11. Patients who are unable to given written informed consent.